Soligenix, Inc. · NASDAQ:SNGX

Soligenix — Investor Presentation (January 2015)

30 slides from Soligenix's investor presentation, Jan 7, 2015

  1. Slide 1: Soligenix corporate presentation

    ((SOLIGENIX OTC QB: SNGX

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products a

  3. Slide 3: Company Highlights

    Company Highlights • Diversified product portfolio in advanced clinical development, targeting indications with $200M+ markets worldwide o Phase 3 program for the treatment of cutaneous T-cell lymphoma (SGX301) • Orphan drug and fast track designations o Phase 3 program for the treatment of pediatri

  4. Slide 4: Development Candidates

    Development Candidates BioTherapeutics Preclinical Phase 1 Phase 2 Phase 3 SGX301 ORPHAN/FAST TRACK DESIGNATION Ph. 3 data 2H 2016* Cutaneous T-Cell Lymphoma (CTCL) SGX942 FAST TRACK DESIGNATION Ph. 2 data 1H 2015* Oral Mucositis in Head & Neck Cancer SGX203 Pediatric Crohn’s Disease** ORPHAN/FAST T

  5. Slide 5: Multiple Potential Value Drivers

    Multiple Potential Value Drivers 2014 2015 2016 SGX301 FDA clearance 1H: Ph. 3 start 2H: Ph. 3 data Ph. 3 study in CTCL in CTCL SGX942 1H: Ph. 2 data in 1H: Ph. 3 start in Oral Mucositis Oral Mucositis 1H: FDA clearance 2H: Ph. 3 start in SGX203* Ph. 3 study Pediatric Crohn’s 2H: Ph. 2b start in 2H:

  6. Slide 6: Experienced Management and Board of Directors

    Experienced Management and Board of Directors • 25 years of experience Christopher J. • Discovery Laboratories (COO) Schaber, MSc, • Acute Therapeutics (Co-Founder) Keith Brownlie, • 35 years of experience CPA • Ernst & Young PhD • Ohmeda Pharmaceuticals President & CEO • The Liposome Company • Wyet

  7. Slide 7: BioTherapeutics

    BioTherapeutics Targeted Approach to Treating Oncology & Inflammation 7

  8. Slide 8: BioTherapeutics Business Segment

    BioTherapeutics Business Segment Commercial targets – unmet medical needs in oncology and inflammation Cutaneous T-Cell Oncology SGX301 Lymphoma Oral Mucositis in SGX942 Head & Neck Soligenix Cancer BioTherapeutics Oncology Supportive Care Segment Oral BDP Acute Radiation (SGX201) Enteritis Autoimmu

  9. Slide 9: SGX301 – Synthetic Hypericin

    SGX301 – Synthetic Hypericin • First-in-class, represents new treatment paradigm – safe, visible light activates topical SGX301 (synthetic hypericin) to treat disease o Hypericin is one of the most powerful photosensitizers in nature o Established mechanism - Generation of singlet oxygen and apoptos

  10. Slide 10: Cutaneous T-Cell Lymphoma (CTCL)

    Cutaneous T-Cell Lymphoma (CTCL) • Class of Non-Hodgkin's Lymphoma (NHL) • Caused by a mutation of T-cells o Most NHLs are B-cell related o Malignant, skin-trafficking T-cells are recruited to the upper dermis and epidermis (by virtue of expression of high levels of the chemokine receptor CCR4) Over

  11. Slide 11: SGX301 for CTCL

    SGX301 for CTCL • First-in-class, proprietary composition represents new treatment paradigm – visible light with topical synthetic hypericin (skin-directed therapy) • Phase 1 study in healthy volunteers demonstrated safety and tolerability Phase 1 & 2 • Phase 2 placebo-controlled, double-blind, mult

  12. Slide 12: SGX301 – Phase 2 Response Rate

    SGX301 – Phase 2 Response Rate Summary of CTCL Lesion Responses to Synthetic Hypericin Ointment Following Six Weeks of Treatment Responders/Totala Percent Respondersa All Hypericin Responders 7/12 58.3%b Hypericin 0.25% Dose 5/9c 55.6%b Hypericin 0.1% Dose 5/12 41.7%b Placebo Responder 1/12 8.3% Not

  13. Slide 13: Clinical Efficacy Before and After – SGX301 and Visible Light

    Clinical Efficacy Before and After – SGX301 and Visible Light CTCL Patch Hypericin Therapy CTCL Patch Pre-Therapy Using Visible Light Post -Therapy 13

  14. Slide 14: SGX94: Regulating the Innate Defense System

    SGX94: Regulating the Innate Defense System • First responder to infection and tissue injury Innate o Mobilizes anti-infective and tissue healing factors Immunity o Mobilizes adaptive immunity o May cause excessive inflammatory response • Synthetic 5 amino acid Innate Defense Regulator (IDR) targeti

  15. Slide 15: Oral Mucositis – Multi-Factorial Disease

    Oral Mucositis – Multi-Factorial Disease • Debilitating side effect of cancer chemotherapy and / or radiotherapy o Massive ulceration of the mouth, tongue, soft palate and oropharynx Mucositis o Results in severe pain, inability to eat, reduced cancer treatment tolerance and significant increases in

  16. Slide 16: Radiation-Induced Mucositis

    Radiation-Induced Mucositis GOLD STANDARD Animal Model of Mucositis related to H&N Cancer • Decreased duration of mucositis by ~50% • Decreased peak severity from 3.4 to 3.0 % Days Score of >/= 3 P < .001 Oral Mucositis Induced in Hamsters by Fractionated Radiation – GOLD STANDARD • On study days 0,

  17. Slide 17: Chemo-Induced Mucositis

    Chemo-Induced Mucositis PROTECTS against chemotherapy damage PROTECTS ALL mucosal tissue Duration of Severe Oral Mucositis Clinical Endoscopy Score %Animals Days with a Score  3 25 M ean Endoscopy Colitis Score (+/-SEM ) Day 4 Day 7 2.0 20 53% reduction 1.5 15 p<.001 10 1.0 p<.05 5 0.5 0 0.0 VEHICL

  18. Slide 18: SGX942 for Oral Mucositis

    SGX942 for Oral Mucositis • Proprietary composition administered as 4-min IV infusion – short plasma half-life, rapid tissue penetration and prolonged pharmacodynamic impact • Phase 1 single and multiple ascending dose, double-blind, placebo-controlled study Phase 1 in 84 healthy volunteers o Safe a

  19. Slide 19: SGX942 – Other Development Targets

    SGX942 – Other Development Targets Multiple potential targets in infectious disease and biodefense with opportunity for non-dilutive funding to support development Target Indications Potential Application s Potential Funding Summary and Potential Next Steps Melioidosis Biodefense – Category B; NIH,

  20. Slide 20: Oral Beclomethasone 17,21-Dipropionate

    Oral Beclomethasone 17,21-Dipropionate • SGX201, SGX203 and OrbeShieldTM are all independent product opportunities based on our orally administered proprietary formulation technology with beclomethasone 17,21-dipropionate (BDP) o Each enables potent, topical corticosteroid effect to treat GI inflamm

  21. Slide 21: SGX203 for Pediatric Crohn's Disease

    SGX203 for Pediatric Crohn’s Disease • Two tablet proprietary formulation of immediate and delayed release BDP Overview o Designed to treat inflammation throughout the GI tract o Positioned as a corticosteroid option with less toxicity than the current standard systemic steroid therapy – prednisone

  22. Slide 22: Vaccine/BioDefense

    Vaccine/BioDefense Addressing Critical Concerns for Industry and Government 22

  23. Slide 23: Vaccine/BioDefense Business Segment

    Vaccine/BioDefense Business Segment Infectious Disease Vaccines ThermoVaxTM Heat Stabilization Platform BioDefense Vaccines RiVaxTM Ricin Vaccine Soligenix BioDefense Vaccine / BioDefense Vaccines Division VeloThraxTM Anthrax Vaccine * Funded by Government OrbeShieldTM Gastrointestinal Acute (Oral B

  24. Slide 24: ThermoVax – Vaccine Thermostability Platform

    ThermoVaxTM – Vaccine Thermostability Platform • Dried vaccine with desirable physical and immunogenic properties • Improved stability and shelf-life at temperatures exceeding 40ºC o Positive Proof of Concept (POC) – 1 year stability data with no degradation • Preservation of native protein structur

  25. Slide 25: RiVax – Ricin Toxin Vaccine

    RiVaxTM – Ricin Toxin Vaccine • Produced as aluminum-adsorbed vaccine o Efficacy against all routes of toxin exposure • Statistically significant (p < 0.002) survival versus controls in non-human primate (NHP) lethal ricin toxin aerosol exposure model Overview o Induction of neutralizing antibodies

  26. Slide 26: OrbeShield for GI ARS

    OrbeShieldTM for GI ARS • Proprietary two tablet immediate and delayed release BDP formulation o Multiple commercial scale cGMP batches manufactured with long-term controlled room temperature stability Overview • Statistically significant survival post radiation exposure versus controls in canine mo

  27. Slide 27: SGX101 for Melioidosis

    SGX101 for Melioidosis • Melioidosis is caused by Burkholderia pseudomallei (Bps) o Frequently resistant to antibiotic treatment o High mortality and relapse rate, despite prolonged therapy • Exclusive Channel Collaboration with Intrexon Corporation o Development of human monoclonal antibody (mAb) t

  28. Slide 28: Significant WW Market Potential

    Significant WW Market Potential $500+ $500 Assumptions(1) 500 Oral Mucositis in H&N Cancer $450 450 90,000 Patients US 90,000 Patients EU 400 Cutaneous T-Cell Lymphoma 20,000 Patients US 350 $ Millions 20,000 Patients EU $300 Pediatric Crohn’s Disease 300 80,000 Patients US $250 80,000 Patients EU 2

  29. Slide 29: Investment Highlights

    Investment Highlights • Diversified product portfolio in advanced clinical development, targeting indications with $200M+ markets worldwide o Phase 3 program for the treatment of cutaneous T-cell lymphoma (SGX301) • Orphan drug and fast track designations o Phase 3 program for the treatment of pedia

  30. Slide 30: Thank You

    THANK YOU www.soligenix.com

Soligenix — Investor Presentation (January 2015) on 6ix